Related references
Note: Only part of the references are listed.Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy
Tommaso Schirinzi et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Dopamine D2 Receptors Enhance Population Dynamics in Primate Prefrontal Working Memory Circuits
Torben Ott et al.
CEREBRAL CORTEX (2017)
Assessment of serum uric acid as risk factor for tauopathies
Tommaso Schirinzi et al.
JOURNAL OF NEURAL TRANSMISSION (2017)
Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria
Guenter U. Hoeglinger et al.
MOVEMENT DISORDERS (2017)
Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings
Tommaso Schirinzi et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2017)
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
Ruth Lamb et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2016)
Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy
Eleonora Fiorenzato et al.
JOURNAL OF NEURAL TRANSMISSION (2016)
PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy
Georg Nuebling et al.
JOURNAL OF NEUROLOGY (2016)
Early Synaptic Dysfunction in Parkinson's Disease: Insights From Animal Models
Tommaso Schirinzi et al.
MOVEMENT DISORDERS (2016)
Interventional trials in atypical parkinsonism
S. Eschlboeck et al.
PARKINSONISM & RELATED DISORDERS (2016)
Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy
Marcello Moccia et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
A clinical and biochemical analysis in the differential diagnosis of idiopathic normal pressure hydrocephalus
Tommaso Schirinzi et al.
FRONTIERS IN NEUROLOGY (2015)
Rate of decline in progressive supranuclear palsy
Irene Litvan et al.
MOVEMENT DISORDERS (2014)
The Phenotypic Spectrum of Progressive Supranuclear Palsy: A Retrospective Multicenter Study of 100 Definite Cases
Gesine Respondek et al.
MOVEMENT DISORDERS (2014)
Progressive Supranuclear Palsy
Lawrence I. Golbe
SEMINARS IN NEUROLOGY (2014)
Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism
Davide Vito Moretti et al.
FRONTIERS IN NEUROLOGY (2014)
Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
Davide Vito Moretti et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Dopamine D-2-agonist Rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients
Alessandro Martorana et al.
NEUROPHARMACOLOGY (2013)
Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER
K. Ray Chaudhuri et al.
PARKINSONISM & RELATED DISORDERS (2013)
Are Frontal Cognitive and Atrophy Patterns Different in PSP and bvFTD? A Comparative Neuropsychological and VBM Study
Julien Lagarde et al.
PLOS ONE (2013)
Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies
Jan-Peer Elshoff et al.
CLINICAL THERAPEUTICS (2012)
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
David R. Williams et al.
LANCET NEUROLOGY (2009)
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease
S. Hoops et al.
NEUROLOGY (2009)
Excessive dopamine neuron loss in progressive supranuclear palsy
Karen E. Murphy et al.
MOVEMENT DISORDERS (2008)
Levodopa responsiveness in disorders with parkinsonism: A review of the literature
Radu Constantinescu et al.
MOVEMENT DISORDERS (2007)
A clinical rating scale for progressive supranuclear palsy
Lawrence I. Golbe et al.
BRAIN (2007)
Share Paper
